Shilpa Medicare (NSE:SHILPAMED) EBIT: ₹3,711 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SHILPAMED Shilpa Medicare Ltd NSE:SHILPAMED
76 GF Score
Price ₹620.25
GF Value ₹387.78
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shilpa Medicare EBIT?

Shilpa Medicare NSE:SHILPAMED -2.76% 76 EBIT is ₹3,711 Mil as of Mar. 2026. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 76/100 and a GF Value™ of ₹387.78 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Shilpa Medicare's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹1,511 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3,711 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shilpa Medicare's annualized ROC % for the quarter that ended in Mar. 2026 was 10.94%. Shilpa Medicare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 24.90%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Shilpa Medicare's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.93%.


Shilpa Medicare  (NSE:SHILPAMED) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shilpa Medicare's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=4242 * ( 1 - 10.51% )/( (0 + 34714.5)/ 1 )
=3796.1658/34714.5
=10.94 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Shilpa Medicare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=6042.8/( ( (0 + max(0, 0)) + (17821 + max(6447.5, 0)) )/ 1 )
=6042.8/( ( 0 + 24268.5 )/ 1 )
=6042.8/24268.5
=24.90 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5188.5 + 3667.9 + 1324.4) - (1424.7 + 0 + 2308.6)
=6447.5

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Shilpa Medicare's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=3710.64/126854.414
=2.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shilpa Medicare EBIT Related Terms


Shilpa Medicare EBIT Historical Data

* Premium members only.

The historical data trend for Shilpa Medicare's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shilpa Medicare EBIT Chart

Shilpa Medicare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,431.99 179.75 1,380.54 2,353.20 4,150.30

Shilpa Medicare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 440.60 683.61 800.98 715.35 1,510.70

NSE:SHILPAMED vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shilpa Medicare EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shilpa Medicare's EV-to-EBIT falls into.


NSE:SHILPAMED
76GF Score
Shilpa Medicare Ltd NSE:SHILPAMED
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shilpa Medicare EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,711 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹3,711 Mil mean?
Shilpa Medicare (NSE:SHILPAMED) has a EBIT of ₹3,711 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shilpa Medicare.
Is Shilpa Medicare's EBIT too high?
Shilpa Medicare's current EBIT is ₹3,711 Mil. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's EBIT compare to ZTS and UTHR?
Shilpa Medicare's EBIT of ₹3,711 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Shilpa Medicare. Shilpa Medicare's current EBIT is ₹3,711 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹387.78, compared to a current price of ₹620.25 — trading 59.9% above its estimated fair value. The current EBIT is ₹3,711 Mil. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current EBIT is ₹3,711 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?

Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued. The current stock price of ₹620.25 is trading 59.9% above its estimated GF Value™ of ₹387.78. GuruFocus considers Shilpa Medicare to be Significantly Overvalued.

Key valuation signals for NSE:SHILPAMED:

  • EBIT: ₹3,711 Mil
  • GF Value™: ₹387.78 vs. price of ₹620.25 (59.9% above fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shilpa Medicare Business Description

Other Exchanges 530549:India
Address Hyderabad Road, No. 12-6-214/A-1, Shilpa House, Raichur, KA, IND, 584135
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score

Get the complete analysis for NSE:SHILPAMED

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹620.25
Price
₹387.78
GF Value